Ilaris for periodic fever syndromes and systemic juvenile idiopathic arthritis in Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, uncontrolled, open-label non-interventional study enrolling pediatric (age 2–18) and adult (19+) patients in Korea who are receiving Ilaris for CAPS, crFMF, TRAPS, HIDS/MKD, or sJIA. The study combines prospective observation with retrospective baseline data for patients who started Ilaris before enrollment and follows participants for up to 2 years of observation after a 2-year enrollment period (total up to 4 years). Treatments follow routine clinical care and approved labeling rather than protocol-driven interventions, and there is no fixed sample size because all eligible treated patients at participating sites will be included. Safety and effectiveness events will be collected and summarized to describe real-world use of Ilaris in these indications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Written informed consent/assent of the patient or their legal representative/parent (≥2 year and \<19 year-old pediatric patient) for voluntarily participating in this study
2. Age: ≥2 year and \<19 year-old pediatric and ≥19 year-old adult hereditary periodic fever syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) patients and ≥2 year and \<19 year-old sJIA patients
3. Patient who have an agreement to be treated or who have already started treatment with Ilaris in accordance with the approved label information

Exclusion Criteria:

1. Patients receiving Ilaris treatment for autoimmune disease other than CAPS, crFMF, TRAPS, HIDS/MKD or sJIA
2. Patients participating in an interventional clinical trial which would have an impact on routine clinical treatment

Where it's running

• Novartis Investigative Site
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reduced intensity conditioning for patients with non-malignant disorders undergoing stem cell transplants

  This study is testing a gentler approach to stem cell transplants for people with non-cancerous disorders to see if it helps them recover better with fewer risks.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT01962415

• Using PET/CT Imaging to Detect Amyloidosis in Patients Treated with Anakinra

  This study is testing a new imaging method to see if it can help find amyloidosis in adults with cryopyrin-associated periodic syndromes who have been treated with anakinra.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06974877

• Allogeneic HCT for Refractory sJIA in Children and Young Adults

  This study tests whether donor blood-forming cell transplantation can help children and young adults with difficult-to-treat systemic JIA, including those with lung involvement.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07845942

• Canakinumab use in FMF and Still's disease patients across real-world care

  This real-world study looks at how people with FMF or Still's disease who were treated with canakinumab fare over at least 6 months.

  Recruiting Novartis · Basel · NCT07517250

• Evaluating GenaKumab for treating active systemic juvenile idiopathic arthritis

  This study is testing a new medication called GenaKumab to see if it helps children and teens with active systemic juvenile idiopathic arthritis feel better and stay safe while using it.

  Recruiting Changchun GeneScience Pharmaceutical Co., Ltd. · Beijing, Benjing and 9 other locations · NCT05925452

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.